C
Claire N. Harrison
Researcher at Guy's and St Thomas' NHS Foundation Trust
Publications - 511
Citations - 24605
Claire N. Harrison is an academic researcher from Guy's and St Thomas' NHS Foundation Trust. The author has contributed to research in topics: Ruxolitinib & Myelofibrosis. The author has an hindex of 66, co-authored 424 publications receiving 19843 citations. Previous affiliations of Claire N. Harrison include St Thomas' Hospital & National Health Service.
Papers
More filters
Journal ArticleDOI
Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis
Andrew C. Perkins,Kate Burbury,Thomas Lehmann,David M. Ross,Andreas Reiter,Vikas Gupta,Claire N. Harrison,Jean-Jacques Kiladjian,Alessandro M. Vannucchi,Marielle J. Wondergem,Robert Pack,Monika Wroclawska,C. Wilke,Angela Zhang,Florian H. Heidel +14 more
TL;DR: Assessing the safety and efficacy of RUX in combination with novel agents may offer superior disease control and transformative clinical benefits, including prolonged progression-free survival and improved cytopenias and QOL, and may reduce the malignant clone and bone marrow fibrosis.
Journal ArticleDOI
Effect of Ruxolitinib On the Incidence of Splenectomy in Patients with Myelofibrosis: A Retrospective Analysis of Data From Ruxolitinib Clinical Trials.
Srdan Verstovsek,Jean-Jacques Kiladjian,Ruben A. Mesa,Alessandro M. Vannucchi,Jason Gotlib,Giovanni Barosi,Hagop M. Kantarjian,Andres Sirulnik,Wei Peng,Victor Sandor,Claire N. Harrison +10 more
TL;DR: Results of this analysis suggest that ruxolitinib reduces the need for splenectomy in patients with MF.
Journal ArticleDOI
Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib
P. Harrington,Katie J. Doores,Jamie G. Saunders,Marc de Lord,Chandan Saha,Thomas Lechmere,Hataf Khan,Ho Pui Jeff Lam,Amy Reilly,Claire Woodley,S. Asirvatham,Richard Dillon,Natalia Curto-Garcia,Jennifer O’ Sullivan,Shahram Kordasti,Kavita Raj,Michael H. Malim,Deepti Radia,Donal P. McLornan,Claire N. Harrison,Hugues de Lavallade +20 more
TL;DR: The humoral and T cell responses induced by sequential doses of vaccination against SARS-Cov-2 in patients with chronic myeloproliferative neoplasms are reported as well as the early protective effect on infection in these patients.
Journal ArticleDOI
CD30/CD123 Expression in Systemic Mastocytosis Does Not Correlate with Aggressive Disease
Mufaddel T Moonim,Thibaud Kossier,Jon van der Walt,Bridget S. Wilkins,Claire N. Harrison,Deepti Radia +5 more
TL;DR: Preliminary data is presented on 43 SM patients seen at Guys and St Thomas' Hospitals NHS Foundation Trust looking at CD30 and CD123 expression with clinical correlates, with no discriminatory marker to allow for identification of SM patients with more aggressive disease.
Journal ArticleDOI
Phazar: A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN [ISRCTN16783472]
Mark Drummond,Charlotte Gaskell,Claire N. Harrison,Adam J. Mead,Christina Yap,Christina Yap,Aimee Jackson,Jennifer Byrne,Fiona Clark,Srinivasan Narayanan,David G. Bowen,Tim C. P. Somervaille,Emma Gudgin,Dragana Milojkovic,Rachel Fletcher,Charlotte K. Brierley,Steve Knapper +16 more
TL;DR: The phase Ib single-arm PHAZAR trial was established to determine maximum tolerated dose (MTD), safety profile and clinical activity of the selective JAK1/2 inhibitor ruxolitinib (RUX) used in combination with AZA to treat MPN-AP and MPn-BP patients.